DDInter474 DDInter992
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Phenylpropanolamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Labetalol
Labetalol {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Labetalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Pseudoephedrine {u} (Compound) resembles {v} (Compound) Isoxsuprine
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine (Compound) resembles Ephedrine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Labetalol (Compound) and Labetalol (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Isoxsuprine (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Isoxsuprine (Compound)